Van K. Morris, MD, discusses the evaluation of circulating tumor as a predictive biomarker for the use of adjuvant chemotherapy in patients with low-risk, stage II colon cancer.
https://www.onclive.com/view/dr-morris-on-the-investigation-of-the-role-of-ctdna-in-stage-ii-crc
